All studies
RecruitingOBSERVATIONAL

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

This study aims to understand how effective new ways of classifying brain tumours are. Doctors use different systems to name and group brain tumours, and recently, new guidelines (cIMPACT-NOW and 2021 WHO) have been introduced. The researchers want to see if these updated classifications do a better job of identifying similar groups of patients than the older system. This is important because knowing more accurate groups helps doctors predict how a tumour might behave and decide on the best treatment. The study will look at information from patients with various brain tumour types to help create clearer recommendations for treating these newly defined conditions. This helps ensure patients receive the most appropriate care.

At a glance

Status
Recruiting
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Enrolment target
1,650
Start
21 Mar 2023
Estimated completion
29 Jul 2038

What is this study about?

Imagine brain tumours are like different types of trees in a forest. For a long time, doctors have been using certain ways to identify and group these 'trees'. Recently, new, more detailed ways of classifying brain tumours have come out, like a new, more advanced guide to the forest. These new guides, called cIMPACT-NOW and the 2021 World Health Organization (WHO) classification, aim to give a clearer picture of each tumour type based on discoveries in science.

This study is like a detective story. The researchers want to see if these new classification methods are better at grouping patients with similar tumours together than the old methods. Why is this important? Because if patients are grouped more accurately, doctors can better understand what to expect from their tumour and which treatments might work best. With many new treatments becoming available, it's vital to know which ones are most suitable for specific tumour types.

The main goal is to use information gathered from patients to help create up-to-date recommendations. These recommendations will guide doctors on how to best treat patients with these newly defined brain tumour types. The study is collecting real-world information about different treatments used by experts, which will help build this knowledge.

Key takeaways

  • This study uses existing medical information to learn about brain tumours.
  • It aims to improve how we classify brain tumours for better treatment.
  • No new treatments or tests are given as part of this study.
  • It helps doctors create better guidelines for future patients.
  • Patients aged 18 and over with certain brain tumours may be included.

Who may be eligible?

To be part of this study, you must be at least 18 years old. You need to have been recently diagnosed with certain types of primary brain tumours, or have a brain tumour that has come back. For the study to work, doctors need to have some of your tumour tissue saved from your initial surgery. They also need to be able to look at your brain scans (like MRI or CT scans) from when your brain tumour was first found. Finally, you would need to give your permission to be included.

If a patient has sadly passed away, their information (such as medical records, tumour samples, or scans) can still be used under specific circumstances. This is only allowed if they agreed to it during their lifetime, or if a close family member gives permission. There are also legal safeguards to ensure this is done respectfully and ethically, and only if there's no record of the patient having objected to their data being used for research.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you at least 18 years old?
  2. Do you have a newly diagnosed brain tumour or one that has come back?
  3. Was some of your tumour tissue saved from your surgery?
  4. Are your brain scans (MRI/CT) from your diagnosis available?
  5. Are you able to give your permission (consent) for your information to be used?
Answer every question to see your result.

What does participation involve?

This is an 'observational' study. This means you wouldn't receive a specific treatment as part of the study itself. Instead, the researchers would collect information about your existing brain tumour and the treatments you are already receiving as part of your standard care. They would look at details from your medical records, such as your diagnosis, the type of treatment you had, and how you responded to it. They would also use samples of your tumour tissue saved from surgery and copies of your brain scans. There are no extra visits or procedures required specifically for this study. The duration of your involvement would depend on how long information is collected on your specific condition as part of their ongoing data collection.

Potential risks and benefits

Since this is an observational study, there are no new medical treatments or procedures involved, so it doesn't carry the physical risks associated with taking new medications or undergoing experimental surgery. The information gathered will help doctors better understand brain tumours and improve care for future patients. Your personal information will be protected, but there's always a small risk of a privacy breach in any data collection. You have the right to withdraw your consent for your data to be used in the study at any time.

Locations (42)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Innsbruck Universitaetsklinik
    Verified postcode
    Innsbruck, Austria· Recruiting
  • Universitaetsklinikum Wien - AKH unikliniken
    Verified postcode
    Vienna, Austria· Recruiting
  • Onze Lieve Vrouw Ziekenhuis
    Verified postcode
    Aalst, Belgium· Recruiting
  • Institut Jules Bordet
    Verified postcode
    Anderlecht, Belgium· Recruiting
  • Universitair Ziekenhuis Brussel
    Verified postcode
    Brussels, Belgium· Recruiting
  • C.H.U. Sart-Tilman
    Verified postcode
    Liège, Belgium· Recruiting
  • AZ Delta - Campus Rumbeke
    Verified postcode
    Roeselare, Belgium· Recruiting
  • CHU Lyon - Hopital neurologique Pierre Wertheimer
    Verified postcode
    Lyon, France· Recruiting
  • Hopital de La Timone
    Verified postcode
    Marseille, France· Recruiting
  • Hopital la Pitie-Salpetriere
    Verified postcode
    Paris, France· Recruiting
  • Knappschaft Krankenhaus Langendreer
    Verified postcode
    Bochum, Germany· Recruiting
  • Universitaetsklinikum Bonn
    Verified postcode
    Bonn, Germany· Recruiting

Common questions

What is a 'primary brain tumour'?

A primary brain tumour is a growth that starts in the brain, rather than spreading there from elsewhere in the body.

What does 'observational study' mean?

It means researchers will just watch and collect information about your existing treatment and health. You won't be given any new treatments or tests specifically for this study.

What is the '2021 WHO classification'?

It's a new, updated way that doctors classify and name different types of brain tumours, based on the latest scientific understanding.

Will this study change my treatment?

No, this study will not change your current treatment. It only collects information about the care you are already receiving.

Will my personal details be kept private?

Yes, your personal and medical information will be handled with strict confidentiality and your identity will be protected.

How to find out more

EORTC HQ

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Observational Study for Assessing Treatment and Outcome of P…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.